Acute lymphoblastic leukemia presenting as cholestatic jaundice in a 7-year-old boy

Jessica Ford1,2, Shane Rainey1,2, Keith Hanson1,2 and Harleena Kendhari1,2

Abstract
This is a case of a 7-year-old boy with acute lymphoblastic leukemia presenting with cholestasis and elevated transaminase levels. Acute lymphoblastic leukemia is the most common malignancy in children and can have variable presenting clinical manifestations. However, cholestasis is less commonly encountered in the pediatric population and can be a diagnostic challenge. We present a case of a 7-year-old boy discovered to have elevated transaminase levels while undergoing an evaluation for motor tics, which subsequently progressed to cholestasis and acute liver failure secondary to acute lymphoblastic leukemia. He demonstrated marked improvement after induction therapy and is in clinical remission. Clinicians should be ever mindful of the potentially unique presentations of childhood leukemia.

Keywords
Cholestasis, gastroenterology, leukemia, oncology

Date received: 20 May 2019; accepted: 19 August 2019

Introduction
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and accounts for almost 25% of all pediatric cancers.1 It is usually classified by cell lineages and often presents with fatigue, pallor, lymphadenopathy, hepatosplenomegaly, and bone pain. However, it can also present with atypical findings and extranodal involvement, including the liver, spleen, testes, and skin. Leukostasis, or symptomatic hyperleukocytosis, can occur when white cell plugs affect the microvasculature, leading to decreased tissue perfusion, but is a rare finding in the lymphoid leukemias. This is a case of a 7-year-old boy who was found to have cholestasis and subsequent acute liver failure secondary to ALL-related leukostasis.

Case presentation
A 7-year-old boy with a history of recent-onset motor tics presented to his pediatrician with 4 days of scleral icterus, decreased appetite, and vomiting. He denied fevers, trauma, diarrhea, easy bleeding and bruising, changes in bowel habits, and recent travel. Other than being treated for streptococcal pharyngitis the week prior, the patient was in his usual state of health and had no other recent illness. During evaluation of tics 2 months before presentation, he had been found to have moderately elevated transaminases, with alanine aminotransferase (ALT) of 322 U/L and aspartate aminotransferase (AST) of 224 U/L. Total bilirubin; a hepatitis panel for hepatitis A, B, and C titers; and head imaging were normal at that time. He was not on any medications, and there was no family history of liver disease or other malignancy. He was evaluated by his pediatrician in clinic for the above symptoms and directly admitted to the hospital for further evaluation.

Physical examination on the day of admission revealed a tired-appearing child with scleral icterus, cervical and inguinal lymphadenopathy, hepatomegaly to 8 cm below the right costal margin, and palpable splenomegaly to 3 cm below the left costal margin. Laboratory evaluation on admission yielded significantly elevated transaminase levels with ALT of 1295 U/L, AST of 1693 U/L, gamma glutamyl transferase
Table 1. Liver function testing during admission and after chemotherapy.

|                | Admit | Day 2  | Day 3  | Day 4  | Day 5  | Day 6  | Day 7  | Day 8  | Day 9  | Day 10 | Day 11 | Post-induction chemotherapy |
|----------------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-----------------------------|
| AST (U/L)      | 1693  | 1284   | 1309   | 1227   | 1385   | 1375   | 1240   | 1266   | 1020   | 1188   | 1298   | 37              |
| ALT (U/L)      | 1295  | 1116   | 1052   | 1016   | 992    | 1086   | 939    | 1004   | 887    | 917    | 954    | 80              |
| Total bilirubin (mg/dL) | 9.3   | 10.0   | 11.1   | 12.4   | 10.7   | 11.5   | 12.5   | 16.2   | 18.4   | 19.1   | 20.5   | 1.6            |
| Direct bilirubin (mg/dL) | 6.8   | 7.4    | 8.0    | 9.2    | 8.3    | 8.8    | 9.2    | 11.8   | 13.1   | 13.8   | 14.0   | 0.9            |
| GGT (U/L)      | 212   | 212    | 213    | 218    | 220    | 287    | 311    | 282    | 243    | 209    | –               |
| Albumin (g/dL) | 3.8   | 3.4    | 3.3    | 3.2    | 3.0    | 3.3    | 3.0    | 3.1    | 3.0    | 2.8    | 2.5    | 4.6            |
| PT (s)         | 14.4  | 14.9   | 14.6   | 14.9   | 15.0   | 15.1   | 15.3   | 16.0   | 16.7   | 17.7   | 18.0   | 15.0           |
| PTT (s)        | 28    | 28     | 28     | 28     | 27     | 27     | 28     | 28     | 30     | 32     | 28    | 22             |
| INR            | 1.1   | 1.2    | 1.1    | 1.1    | 1.2    | 1.2    | 1.2    | 1.3    | 1.3    | 1.5    | 1.5   | 1.2            |

AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio.

(GGT) of 212 U/L, and direct bilirubin of 6.8 mg/dL. A complete blood count (CBC) showed mild leukocytosis with a white blood cell count of 15.7 × 10^3 cells/µL, a normal hemoglobin of 13.7 g/dL, and mild thrombocytopenia with platelets of 195 × 10^3 cells/µL. Differential was notable for 44% lymphocytes, 31% neutrophils, 14% eosinophils, 3% basophils, and 2% monocytes. Coagulation profile, lipase, antinuclear antibody, thyroid studies, Epstein–Barr virus titers, and a repeat hepatitis panel were within normal limits. An abdominal ultrasound demonstrated diffuse gallbladder wall thickening and surrounding lymphadenopathy with nonspecific hepatomegaly.

On the second day of admission, he developed a new fever for which he was started on antibiotics for presumed ascending cholangitis. Gastroenterology was consulted and recommended a hepatobiliary iminodiacetic acid scan, which showed increased uptake in the hepatic parenchyma with poor hepatic clearance and no filling of the gallbladder. Further evaluation, including comprehensive infectious testing, was negative. Labs were trended while undergoing evaluation (Table 1). CBC remained stable with continued mild leukocytosis and mild thrombocytopenia with no other significant abnormalities, and transaminases remained significantly elevated. On hospital day 11, the direct bilirubin peaked at 14.2 mg/dL and he developed acute liver failure with a prothrombin time (PT) of 18 s, an international normalized ratio (INR) of 1.5, and an albumin of 2.5 g/dL. Supportive treatments were given including glutathione supplementation, vitamin K, and ursodiol. He was then transferred to a quaternary center where a liver biopsy was performed and a presumptive diagnosis of autoimmune hepatitis was made. He was started on 60 mg of prednisone daily with improvement in his direct hyperbilirubinemia and coagulopathy. His hepatic pathology report returned with findings of atypical lymphocytes on microscopic examination, suggestive of malignancy. He then underwent a bone marrow biopsy which was consistent with pre-T-cell ALL.

He was transferred back to the local tertiary center and transitioned to dexamethasone; however, further chemotherapy was delayed due to continued high direct bilirubin. After 3 weeks of steroid treatment, his bilirubin level was low enough to begin induction chemotherapy with vincristine and daunorubicin in addition to dexamethasone. He was minimal residual disease–negative 1 month later at the end of induction and remains in remission after 15 months of maintenance therapy.

Discussion

Cholestasis is an infrequent presenting complaint in the pediatric population and usually manifests with conjugated hyperbilirubinemia. A conjugated bilirubin level greater than 2 mg/dL or greater than 20% of the total bilirubin level is diagnostic of conjugated hyperbilirubinemia. This condition is never considered normal and always warrants further evaluation.

The differential diagnosis can be separated into obstructive and hepatocellular etiologies. Cholelithiasis can cause obstruction of the common bile duct and resulting jaundice. Choledochal cysts and other obstructive lesions such as an annular pancreas can also obstruct bile flow and lead to jaundice, although these conditions more commonly present in the infantile period. Rarely, parasitic infections, primary sclerosing cholangitis, and hematologic malignancy may present with obstructive jaundice. Hepatocellular causes commonly include viral hepatitis and medication-induced injury, as well as autoimmune hepatitis, Wilson’s disease, alpha-1-antitrypsin deficiency, cystic fibrosis, Dubin–Johnson syndrome, and Rotor syndrome. Initial testing includes total and conjugated bilirubin, AST and ALT, alkaline phosphatase, GGT, and synthetic function markers such as PT and INR. Ultrasonography is useful to evaluate for gallstones, choledochal cysts, and other obstructive lesions. If the cause is not readily determined after thorough history, physical examination, and laboratory and radiographic evaluation, liver biopsy is necessary to establish the diagnosis. Management is directed toward the underlying pathology; however, ensuring adequate nutrition, optimizing levels of fat-soluble vitamins, and monitoring for long-term sequelae of chronic liver disease are necessary in all patients.
ALL is the most common malignancy in children, of which T-cell ALL (T-ALL) accounts for approximately 15% of cases.1,4,5 Common clinical manifestations include fatigue, pallor, hepatosplenomegaly, lymphadenopathy, and bone pain. Nearly 50% of patients with T-ALL present with a mediastinal mass and related sequelae such as superior vena cava syndrome or airway obstruction.6 Extranodal involvement is less common but is usually found in the skin and testes. Direct abdominal involvement is rare but primarily involves the liver and spleen. Leukocytosis is another common presenting finding, as approximately 20% of children will present with a white blood cell count above 50,000/mm3.7 Other common laboratory findings include leukocytopenia, thrombocytopenia, transaminitis, and elevated levels of lactate dehydrogenase, uric acid, and other markers of tumor lysis.

Treatment with intensive chemotherapy is aimed at eliminating leukemic cells from the bone marrow and reestablishing normal hematopoiesis. Further therapy is selected based on presenting symptoms, including steroids to relieve venous congestion in the presence of a mediastinal mass. Overall survival rates for ALL have dramatically improved over the past few decades and now approach 90% at 5 years after diagnosis.8,9

Despite the frequent findings of hyperleukocytosis in acute leukemia, leukostasis is a relatively rare complication in ALL compared to both acute and chronic myeloid leukemia.7 When present, it commonly affects the pulmonary and central nervous systems, manifested by hypoxemia, respiratory distress, headache, dizziness, confusion, and blurry vision. Coagulation abnormalities indicative of liver involvement are also observed in more than 20% of patients with ALL-related leukostasis.10 However, some patients may present with leukostasis without hyperleukocytosis, making the clinical diagnosis significantly more difficult. In the present case, despite a relatively normal white blood cell count without blasts on his CBC, pathology showed atypical lymphocytes invading the liver sinusoids, suggestive of leukostasis-related hepatocellular damage and inflammation. While there are reports in the literature of pediatric B-cell ALL and adult T-ALL presenting with cholestasis, we found none describing cholestatic jaundice as the presenting symptom in pediatric T-ALL.11-13

Our case was challenging in several ways. First, the lack of obvious hematological findings obscured the diagnosis. Several case reports describing cholestatic jaundice as the presenting symptom of ALL had concomitant findings such as pancytopenia or a mediastinal mass as clues to the diagnosis, which were not identified in our case.11-13 Second, the standard induction treatment of ALL involves many hepatotoxic agents, including vincristine and daunorubicin. Unfortunately, due to his hyperbilirubinemia, these drugs were unable to be used initially as part of his treatment. Therefore, he received induction therapy with dexamethasone for 3 weeks until his bilirubin trended down enough to begin additional chemotherapy agents. Vincristine and daunorubicin were then used at 50% and 25% of their standard dosages in an attempt to mitigate their hepatotoxicity in the setting of recent liver failure. Asparaginase was not used during his induction therapy due to the risk of severe hepatotoxicity. While other potentially less hepatotoxic induction regimens can be used in treating ALL in its initial stages, the most common induction regimen for T-ALL involves the above drugs.14 Finally, our patient needed continued monitoring of his liver enzymes and synthetic function markers, necessitating multiple additional clinic and lab visits during his initial diagnosis and therapy. Continued supportive care was also required including ursodiol for cholestasis and gallstone prevention. There have also been reports of levocarnitine being useful in treating and preventing chemotherapy-related hepatic injury, although it was not used in our patient.15

**Conclusion**

We present a rare case of pediatric ALL presenting with cholestasis and acute liver failure. ALL is the most common malignancy in children and can present with atypical findings such as leukostasis affecting any organ, including the liver. Clinicians should keep ALL on their differential diagnosis of the child presenting with acute liver failure. Finally, although rare in the pediatric population, clinicians should be aware of the differential diagnosis, workup, and management of a child presenting with cholestatic jaundice, as seen in our patient.

**Author Contributions**

J.F., K.H., and H.K. contributed to conception and design. J.F. and S.R. drafted the manuscript. J.F., S.R., K.H., and H.K. reviewed and critically revised the manuscript for important intellectual content.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The publication of this study was funded by the UIC Research Open Access Article Publishing (ROAAP) Fund.

**Informed consent**

Written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article.
ORCID iD
Shane Rainey https://orcid.org/0000-0001-9568-3008

References
1. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64(2): 83–103.
2. Gottesman LE, Del Vecchio MT and Aronoff SC. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatr 2015; 15: 192–200.
3. Brumbaugh D and Mack C. Conjugated hyperbilirubinemia in children. Pediatr Rev 2012; 33: 291–391.
4. Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119(1): 34–43.
5. Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol 2017; 18(6): 719–731.
6. Chiaretti S, Vitale A, Cazzaniga G, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica 2013; 98(11): 1702–1710.
7. Nguyen R, Jehs S, Zhou Y, et al. The role of leukapheresis in the current management of hyperleukocytosis in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2016; 63: 1546–1551.
8. Hunger SP and Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015; 373: 1541–1552.
9. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol 2012; 30(14): 1663–1669.
10. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39(1–2): 1–18.
11. Patel KJ, Latif SU and deCalaca WM. An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report. J Hematol Oncol 2009; 2: 12.
12. Siddique M, Popalzai M, Aoun N, et al. Precursor B-cell acute lymphoblastic leukemia presenting as obstructive jaundice: a case report. J Med Case Rep 2011; 5: 269.
13. Chang LS, Yu HR, Chen YC, et al. Acute lymphoblastic leukemia presented as severe jaundice and hyperferritinemia: a case report. J Pediatr Hematol Oncol 2011; 33(3): e117–e119.
14. Kaplan JA. Leukemia in children. Pediatr Rev 2019; 40: 319–329.
15. Schulte RR, Madiwale MV, Flower A, et al. Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. Leuk Lymphoma 2018; 59(10): 2360–2368.